Geneva, Switzerland, January 8, 2015 – Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks used for drug discovery to commercial manufacturing, announced today the first therapeutic biologic generated with the Selexis SUREtechnology Platform™ has been approved for market.
“This market approval represents a major milestone for Selexis,” said Dr. Igor Fisch, CEO, Selexis SA. “There are currently 56 clinical programs utilizing the SUREtechnology platform, including two Phase 3 programs. The increasing number of Selexis generated Research Cell Banks used in clinical programs, and now in a marketed product, is validation of our on-going scientific innovation and our commitment to delivering the highest quality work in biologic drug discovery and manufacturing.”
The Selexis SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel human DNA-based elements that control the dynamic organization of chromatin across mammalian cells. These elements increase transcription rates of transgenes by rendering the expression cassette independent of the locus of integration and thus allowing higher and more stable expression of any recombinant proteins. The SUREtechnology Platform™ improves the way cells are used in the discovery, development and manufacturing of recombinant proteins.
The Selexis SURE CHO-M Cell Line™ is a proprietary high-performance mammalian cell line derived from CHO-K1 cells. The genome of Selexis SURE CHO-M Cell Line™ has been fully sequenced and is used to characterize the sequence of the transgene, identify transgene integration loci and to document the monoclonality of cell populations. Selexis SURE CHO-M Cell Line™ is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Finally, growth and production properties of the Selexis SURE CHO-M Cell Line™ are well defined, and the feed strategy optimized allowing faster and more efficient scale-up into bioreactors.
